Boris Jordan

Zuanic thinks that it could raise the cash piece from one dollar to two dollars and fifty cents a share before its debt would become a problem.

Uh, Boris Jordan is calling the Organigram talks a travesty to the process.

But the real question isn't Organigram, it's whether big tobacco wants to own Aurora.

Um, and there's a governance question here too.

And what about any upcoming big conversations with any MSOs?

Yeah, I think we're going to have on Boris Jordan.

I can't say the date because I actually don't know, but it's coming up.

And also, I think some thoughtful analysis about that deal in particular, because I live in Canada.

Um, I'm gonna get to you, Ben and Brian, in a second, but I'll get to you with this question.

How are you guys with math? Because, um, Boris Jordan, the CEO of-

[laughs]

... of, of Curaleaf wants you to know that poop emoji plus poop emoji equals three poop emojis.

I ...

The ...

Is Boris Jordan kind of on tilt now? Like, he's using poop emojis, he's talking about a travesty.

Is it a travesty? Like, and, and he's, like, claiming, like, foul on, on the process.

And so when you are a contract grower, you're going to choose a strain to get the most yield to maximize the amount you're getting paid versus a company like ours that's extremely focused on the consumer because we're selling through a brand all the way through, understanding what they're looking for, um, getting that wonderful elevated experience for them, and consistently delivering it to deliver a brand promise.

So there's a big mismatch, and I think you can hear that when you hear people like Boris Jordan speaking about the suppli- supply challenges that they have.

You know, he says, "We've got the customers and the demand." Building that consistency is what builds a brand promise, and we saw in the early days of Canadian cannabis certainly a lot of disappointment, a lot of money spent on building brands, and then those brands aren't the brands that are on shelves today because of the lack of follow-through on those promises.

So I think there's a real opportunity for companies like ours because of the consistency in what we do in, it's, in particular in premium, um, to, to take advantage of that.

I want to hear different companies, different views and what they're willing to say about the hemp ban, the impact of it, the impact of their particular markets.

And there again, Ben Kovler might have a different view than Boris Jordan, might have a different view than Kim Rivers, might have a different view than Jason Weil.

I shouldn't say might, I know does.

Everybody, they have different views.

Listen, tell Omar we say hi.

Uh, miss talking to him every single day, but, uh, all in all, job well done, and, uh, got more people asking, uh, how good of friends you and Boris Jordan are, so we'll just leave it at that.

[laughs]

Good friends.

These are all things that normalize the industry.

Boris Jordan at the Ignited conference in June talked about not uplisting yet because there's not enough institutional support underneath that.

But in the next breath, he said for the first time, he's now receiving inbound inquiries about his business from the major institutions that we think of as major institutions.

And that's the first time, whether that's big private equity, whether that's big banking, wanting to deploy significant capital, it's the first time he said that he's got inbound calls and people actually want to speak to him about cannabis.

It's second major Canadian benchmark after any S&P TSX composite back in September of last year.

CEO Boris Jordan, he put it simply.

And that was every index Curaleaf joins brings its shares in front of a set of new passive and active institutional funds.

You had some really good points here that you made in this morning's newsletter.

And Aurora also reported having roughly $149 million in cash.

canadian i should say in no debt when it filed its directors circular earlier this month so really my read on this now is this is simply not just a disagreement over valuation it's becoming a regulatory fight over how aurora has conducted itself while the bid is outstanding so a lot is going to be determined over the next 90 to 95 days and as we learned earlier this week from chairman and ceo boris jordan from cureleaf we had an ama A, if you missed it, make sure to check that out from Thursday.

He just wants to have a conversation.

So these next 90 to 95 days, we'll be telling as to whether or not this actually falls into place.

And we've also reached out to the Aurora team as well to see if they would come on and really speak on their end of this whole hostile bid takeover as well.

So that remains to be seen.

But give credit to Boris Jordan for making himself available earlier this week on our platform.

let's now move to the earnings front and how about high tide again they reported another record quarter with revenue reaching 198.8 million up 33 percent year over year and 11 percent sequentially big numbers adjusted EBITDA reached 16.2 million while the company is now reaching an $800 million annualized revenue run rate.